Search Results - "Mulvey, Therese Marie"

American Society of Clinical Oncology Identifies Five Key Opportunities to Improve Care and Reduce Costs: The Top Five List for Oncology by SCHNIPPER, Lowell E, SMITH, Thomas J, RAGHAVAN, Derek, BLAYNEY, Douglas W, GANZ, Patricia A, MULVEY, Therese Marie, WOLLINS, Dana S

Get full text

Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer by Smith, Sonali M, Wachter, Kerri, Burris, 3rd, Howard A, Schilsky, Richard L, George, Daniel J, Peterson, Douglas E, Johnson, Melissa L, Markham, Merry Jennifer, Mileham, Kathryn F, Beg, Muhammad S, Bendell, Johanna C, Dreicer, Robert, Keedy, Vicki L, Kimple, Randall J, Knoll, Miriam A, LoConte, Noelle, MacKay, Helen, Meisel, Jane Lowe, Moynihan, Timothy J, Mulrooney, Daniel A, Mulvey, Therese Marie, Odenike, Olatoyosi, Pennell, Nathan A, Reeder-Hayes, Katherine, Smith, Cardinale, Sullivan, Ryan J, Uzzo, Robert

Get full text

Inpatient chemotherapy for patients with advanced solid tumors: A single-center observational study by Soumerai, Tara, Lei, Matthew, Mulvey, Therese Marie

“…Abstract only 158 Background: We sought to identify a population of patients with advanced-stage solid tumor diagnoses for whom inpatient chemotherapy is…”
Get full text

Developing machine learning algorithms incorporating patient reported outcome measures to predict acute care events among patients with cancer by Roberts, Thomas J, McGuire, Jessica, Temel, Jennifer S., Kamdar, Mihir, Greer, Joseph A., Mulvey, Therese Marie

“…1516 Background: Clinical trials have shown that collecting patient-reported outcome measures (PROMs) can improve outcomes among oncology patients. However,…”
Get full text

Patient-reported outcomes: Completion, access, and equity by McGuire, Jessica, Hubbell, Harrison Taylor, Hochberg, Ephraim P., Foley, Cara, Ryan, David P., Mulvey, Therese Marie

“…141 Background: Patient Reported Outcomes CTCAE (PROM) completion has demonstrated improvements in survival for patients with advanced cancer. Little is known…”
Get full text

Mortality among oncology patients with multiple unplanned hospital admissions by Roberts, Thomas J, McGuire, Jessica, Temel, Jennifer S., Lage, Daniel E, Greer, Joseph A., Mulvey, Therese Marie

“…6578 Background: Previous work has shown that patients with solid tumors with an unplanned hospital admission have a median overall survival of approximately…”
Get full text

Comparison of the cell-free DNA genomics in patients with metastatic breast cancer (MBC) who develop brain metastases versus those without brain metastases by Vidula, Neelima, Niemierko, Andrzej, Hesler, Katherine, Isakoff, Steven J., Juric, Dejan, Spring, Laura, Mulvey, Therese Marie, Younger, Jerry, Moy, Beverly, Ellisen, Leif W., Bardia, Aditya

“…Abstract only 1094 Background: The genomics of patients with metastatic breast cancer (MBC) who develop brain metastases (BM) is not well understood given the…”
Get full text

Pilot study of iPad-based patient-reported outcomes at the MGH Cancer Center by Parikh, Aparna Raj, Soriano, Margaret, Hochberg, Ephraim P., McLeish, Courtney, Lennes, Inga Tolin, Souza, Elizabeth, Mulvey, Therese Marie

“…Abstract only 190 Background: Patient reported outcomes (PROs) have been shown to improve outcomes in cancer patients in clinical trials and have also been…”
Get full text

Emergency department (ED) utilization among patients with cancer receiving intravenous (IV) chemotherapy by Nipp, Ryan David, Azoba, Chinenye, Vyas, Austin, Kay, Paul, Fuh, Charn-Xin, Wang, Irene, Mai, Minh, Soriano, Margaret, Mulvey, Therese Marie

“…Abstract only 22 Background: ED utilization among patients with cancer is often cited as a potential metric to improve the quality of oncology care. However,…”
Get full text

Characteristics associated with hospitalization for patients with cancer receiving chemotherapy who present to the emergency department (ED) by Nipp, Ryan David, Azoba, Chinenye, Vyas, Austin, Kay, Paul, Fuh, Charn-Xin, Wang, Irene, Mai, Minh, Soriano, Margaret, Mulvey, Therese Marie

“…Abstract only 23 Background: Patients with cancer receiving chemotherapy often present to the ED and require hospitalization to manage acute issues. However,…”
Get full text

Antineoplastic Therapy Administration Safety Standards for Adult and Pediatric Oncology: ASCO-ONS Standards by Siegel, Robert D, LeFebvre, Kristine B, Temin, Sarah, Evers, Amy, Barbarotta, Lisa, Bowman, Ronda M, Chan, Alexandre, Dougherty, David W, Ganio, Michael, Mulvey, Therese Marie, Ouzts, Amanda, Polovich, Martha, Salazar-Abshire, Maritza, Sydenstricker, Christine Marie, Tsai, Susan

“…To update the American Society of Clinical Oncology (ASCO)-Oncology Nursing Society (ONS) standards for antineoplastic therapy administration safety in adult…”
Get full text

Phase 2 study of response-guided neoadjuvant sacituzumab govitecan (IMMU-132) in patients with localized triple-negative breast cancer: Results from the NeoSTAR trial by Spring, Laura, Tolaney, Sara M., Desai, Neelam Vijay, Fell, Geoffrey, Trippa, Lorenzo, Comander, Amy H., Mulvey, Therese Marie, McLaughlin, Shannon, Ryan, Phoebe, Rosenstock, Aron S., Garrido-Castro, Ana Christina, Lynce, Filipa, Moy, Beverly, Isakoff, Steven J., Tung, Nadine M., Mittendorf, Elizabeth A., Ellisen, Leif W., Bardia, Aditya

“…512 Background: Sacituzumab govitecan (SG), a novel antibody-drug conjugate in which the topoisomerase 1 inhibitor SN-38 (active metabolite of irinotecan) is…”
Get full text

Time to Focus on Inpatient Safety: Revision of the American Society of Clinical Oncology/Oncology Nursing Society Chemotherapy Administration Safety Standards by Jacobson, Joseph O., Mulvey, Therese Marie

Get full text

Phase II study of adjuvant endocrine therapy with CDK 4/6 inhibitor, ribociclib, for localized ER+/HER2- breast cancer (LEADER) by Spring, Laura, Griffin, Colleen, Isakoff, Steven J., Moy, Beverly, Wander, Seth Andrew, Shin, Jennifer, Abraham, Elizabeth, Habin, Karleen, Patel, Jaymin M., Comander, Amy H., Mulvey, Therese Marie, Bardia, Aditya

“…Abstract only 531 Background: Given the success of CDK 4/6 inhibitors for ER+/HER2- metastatic breast cancer, there is much interest in exploring these agents…”
Get full text

Considering cost and value with patients in clinic by Peppercorn, Jeffrey M., Quain, Katharine M., Sepucha, Karen, Dizon, Don S., Moy, Beverly, Spring, Laura, Mulvey, Therese Marie, Shin, Jennifer Adrienne, Perez, Giselle Katiria

“…Abstract only…”
Get full text

Clinical outcomes of patients with stage IV cancer receiving immune checkpoint inhibitors in the inpatient setting by Durbin, Sienna, Zubiri, Leyre, Niemierko, Andrzej, Petrillo, Laura A, Bardia, Aditya, Sullivan, Ryan J., McEwan, Corey, Mulvey, Therese Marie, Allen, Ian Matthew, Lawrence, Donald P., Cohen, Justine Vanessa, Hochberg, Ephraim P., Ryan, David P., Reynolds, Kerry Lynn

“…Abstract only 6634 Background: Immune checkpoint inhibitors (ICI) represent a major leap in the treatment of many cancers. Use has rapidly expanded in recent…”
Get full text

Quality improvement interventions to reduce chemotherapy dose-modification ordering errors at a large academic medical center by Soriano, Margaret, Chang, Anne, Galway, Aralee, Listro, Laura, Liu, Evaline, McGuire, Jessica, Mulvey, Therese Marie, O'Donoghue, Sheila, Parikh, Aparna Raj, Rosato, Erika, Ryan, David P., White, Lawren, Woolwine, Melissa Anne, Isakoff, Steven J.

“…Abstract only 264 Background: Despite clear advantages of Electronic Health Records (EHR) systems for safe cancer chemotherapy administration, persistent…”
Get full text

A multicenter analysis of abemaciclib after progression on palbociclib in patients (pts) with hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC) by Wander, Seth Andrew, Zangardi, Mark, Niemierko, Andrzej, Kambadakone, Avinash, Kim, Leslie SL, Xi, Jing, Pandey, Apurva Kumari, Spring, Laura, Stein, Casey, Juric, Dejan, Kuter, Irene, Moy, Beverly, Mulvey, Therese Marie, Vidula, Neelima, Isakoff, Steven J., Yuen, Megan, Brufsky, Adam, Ma, Cynthia X., O'Shaughnessy, Joyce, Bardia, Aditya

“…Abstract only 1057 Background: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) are widely used for pts with HR+/HER2- MBC. The MONARCH-1 trial of abemaciclib…”
Get full text

Capturing High-Value Cancer Care in the Wild by Mulvey, Therese Marie, Peppercorn, Jeffrey

Get full text